Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

NCT02927912 · View on ClinicalTrials.gov ↗

Study Summary

This phase II trial studies the side effects of intraoperative electron beam radiotherapy boost and to see how well it works in treating patients with stage I-II breast cancer undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to the tumor cavity during the breast surgery before reconstruction may be a better way to kill tumor cells and shrink tumors.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • RADIATION Radiation Therapy
  • PROCEDURE Lumpectomy
  • RADIATION Electron Beam Therapy

Study Locations (5)

Ohio

  • University Hospitals — Cleveland
  • Ohio State University Comprehensive Cancer Center — Columbus

North Carolina

  • University of North Carolina — Chapel Hill

South Dakota

  • Avera Cancer Institute — Sioux Falls

Montreal

  • Centre Hospitalier de I'Universite de Montreal — Québec

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2017-10-16
Est. Completion 2026-11-30
Phase Phase 2

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02927912

The ClinicalTrials.gov registry entry for NCT02927912 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 291 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Stage IIA Breast Cancer appearing as the primary indexed condition, and to 5 interventions — of which Quality-of-Life Assessment is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02927912 reports 5 study locations spanning 4 distinct geographic areas — top geographies include Ohio, North Carolina, South Dakota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02927912 about?

NCT02927912 is a clinical study titled "Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction". This phase II trial studies the side effects of intraoperative electron beam radiotherapy boost and to see how well it works in treating patients with stage I-II breast cancer undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to the tumor cavity during the breas...

What is the current status of trial NCT02927912?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2017-10-16. Estimated completion is 2026-11-30.

What conditions does trial NCT02927912 study?

This clinical trial studies the following conditions: Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02927912?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Radiation Therapy (RADIATION), Lumpectomy (PROCEDURE), Electron Beam Therapy (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02927912?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 291 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02927912 being conducted?

This trial has 5 study locations across North Carolina, Ohio, South Dakota, Montreal. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial